DX (Group) PLC non-executive director Russell Black has bought 60,500 shares in the parcels delivery group, sending the shares 7.9% higher to 17p.
Black paid an average of 16.5p for his shares and now has a holding of 2.54mln, equivalent to about 0.44% of the issued share capital of DX.
1.30pm: OptioBiotix surges on back od new distribution deal
OptiBiotix Health PLC (LON:OPTI) rose 11% to 55.5p after it announced an exclusive distribution agreement.
The agreement is with United Italian Trading Corporation (UITC) for its SlimBiome Medical weight management product in the Singaporean market.
UITC is a pharmaceutical and medical device distribution firm serving a range of clients including hospitals, polyclinics, medical specialists clinics, family physician clinics, pharmacies, supermarkets and department stores.
12.30pm: Bluebird of happiness
The bluebird of happiness visited the shareholders of Bluebird Merchant Ventures Limited (LON:BMV) on Monday.
The shares rose 18% to 5.35p the gold development group said its funding partners in South Korea have accelerated their schedule of funding for the South Korean projects ahead of the completion of the process that will see Bluebird increase its stake from 50% to 100% in the Gubong and Kochang gold projects.
The company has received the first tranche of funding that will enable progress on the ground in South Korea and for construction to commence. The funding is non-dilutive and is a straight pre-payment for gold with no interest, Bluebird stressed.
11.30am: Bahamas enjoys a spell in the sun
The company is counting down to the high-impact Perseverance-1 well, in the Bahamas, while a work programme in Trinidad also promises to significantly boost production volumes.
It comes after the company’s acquisition of Columbus Energy Resources closed in August, which brought a portfolio of production assets in Trinidad along with further exploration acreage to progress in the future.
10.30am: Brand Architekts fails to scrub up well as it dives into the red
The shares slipped 5.4% lower to 113.5p after the group, which recently sold its contract manufacturing business, made a loss from continuing operations of £4.3mln in the 52 weeks to June 27 compared to a profir the year before of £1.8mln.
Revenue from continuing operations slipped to £16.3mln from £19.7mln the year before. A 16% decline in UK sales was driven by low consumer confidence and pressure within the retail environment, and the impact of store closures as a result of the outbreak of COVID-19, the group said,
International sales declined by 24% following the heavy impact of currency devaluation in Turkey, the effect of increased tariffs on cosmetic goods shipped from China to the USA and the impact of COVID-19 across several of our markets, it added.
9.30am: Reach outperforming expectations as digital advertising revenues recover
The Daily Mirror and Daily Express owner said it is performing materially ahead of market expectations with the newspapers group seeing a strong recovery in the digital advertising market since the worst impacts of COVID-19 in April.
Revenue in the first half of 2020 was down 17.5% year-on-year at £290.8mln, partly reflecting the impact of the coronavirus pandemic. Revenue in the third quarter was down 15.0% after declining by 27.5% in the second quarter.
Evidence for positive disease impact clocked in at a response rate of 54%, while only one dose-limiting toxicity event (in this case, raised blood pressure) occurred during safety testing and this was at the maximum dosage used of 8 mg/kg.
“The headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate,” said Suzy Dilly, the chief executive of ValiRx.
Update: Shares in ValiRx subsequently turned lower, trading 11% in the red at 47.5p in mid-morning trading.
Proactive news headlines
OptiBiotix Health PLC (LON:OPTI) said it has signed an exclusive distribution agreement with United Italian Trading Corporation (UITC) for its SlimBiome Medical weight management product in the Singaporean market.
ANGLE PLC (LON:AGL, OTCQX:ANPCY) said it has submitted for regulatory approval in the US its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC).
Symphony Environmental Technologies PLC (LON:SYM) said its d2w biodegradable plastic technology has been incorporated into a new 100ml security bag that will be trialled at airports in Aberdeen, Glasgow and Southampton operated by AGS Airports Ltd.
Incanthera PLC (AQSE:INC) has received positive data from a skin sensitisation study of its Sol skin cancer technology, which demonstrates it is “non-irritant”.
e-Therapeutics PLC (LON:ETX) said it has expanded its scientific advisory board with the appointment of Bill Harte and John Mattick.
Scotgold Resources Ltd (LON:SGZ) continues to build the resource inventory at the Cononish gold and silver mine. The company has identified gold and silver anomalies to the north-east of the mine that are consistent with the ‘Mother Vein’ structure.
NQ Minerals PLC (AQSE:NQMI)(OTCQB:NQMLF) has boosted production and processing rates at its Hellyer mine in Australia to 165 tonnes per hour. Plans are being finalised to increase production further to 180 tph, equivalent to about 1.5mln tonnes per year.
Mosman Oil and Gas Ltd (LON:MSMN) told investors that the Stanley-4 well is flowing around 155 barrels of oil per day. Oil sales from the well are due to start this week, the company noted in a statement.
Ncondezi Energy Ltd (LON:NCCL) has moved to put investors’ minds at rest over backing for the Ncondezi 300 megawatt power project in Tanzania. Lead investor CMEC has compiled a preferred list of partners who are familiar with the project and has indicated that sealing a deal with a new technology partner would take about a month to complete if required.
Ceres Power Holdings PLC (LON:CWR) delivered revenue growth in the year to the end of June despite the coronavirus (COVID-19) pandemic delaying some sales. The fuel cell and electrochemical technology firm said the year saw a 21% increase in revenue and other operating income to £19.9mln from £16.4mln the year before.
Bahamas Petroleum Company PLC (LON:BPC) is looking forward to a “potentially company-making” next six months. The company is counting down to the high-impact Perseverance-1 well, in the Bahamas, while a work programme in Trinidad also promises to significantly boost production volumes.
EQTEC PLC (LON:EQT) chief executive David Palumbo told investors that there’s a growing awareness among potential customers of the company’s proposition. Palumbo said that 2021 is seen by EQTEC as “potentially exponential” in terms of deal closures and revenue growth.
Crossword Cybersecurity PLC (LON:CCS) has reported strong growth in orders for its Rizikon Assurance supply chain risk management platform in the first half of its current year. In its results for the six months ended June 30, the AIM-listed firm reported that orders for Rizikon Assurance were up 41% year-on-year (YOY), while recurring revenue from the firm’s consulting services had doubled over the same period compared to 2019.
Salt Lake Potash Ltd (ASX:SO4) (LON:SO4) (OTCMKTS:WHELF) is set for a transformational year as it heads towards the first sulphate of potash production from the Lake Way project in the first quarter of 2021.
Anglesey Mining PLC (LON:AYM) lost £305,000 in the year to March, up slightly from the £234,000 lost in the corresponding period a year earlier. The company ended the financial year with £95,000 in cash, although after the period end, in August, it raised £200,000 in a placing.
Arkle Resources PLC (LON:ARK) turned in a loss of €220,000 for the six months to June 2020. The company closed out the period with €252,000 in cash. However, a further £600,000 was raised in August, covering expenses for the next 18 months.
Genedrive PLC (LON:GDR) will issue £1mln of shares to BGF Investments LP after the private equity group exercised its right to convert part of its £2.5mln loan note. The molecular diagnostics company will allot 4,478,681 new ordinary shares and pay roughly £134,000 in cash to BGF, reflecting the accrued interest owed on this tranche of the loan.